What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
The scientist’s investigation covers issues in Internal medicine, Chronic lymphocytic leukemia, Leukemia, Immunology and Oncology.
He has researched Internal medicine in several fields, including Gastroenterology and Surgery.
His Chronic lymphocytic leukemia research includes themes of Cancer research, Alemtuzumab and CD20.
His Leukemia research integrates issues from Clinical trial, Survival rate, Myeloid leukemia, Lymphoma and Pharmacology.
His work deals with themes such as Philadelphia chromosome, Toxicity and Transplantation, which intersect with Immunology.
His Oncology research is multidisciplinary, relying on both Cancer, Hematology, Refractory Chronic Lymphocytic Leukemia, [email protected] and Chronic myelogenous leukemia.
His most cited work include:
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (1539 citations)
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (971 citations)
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia (857 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Oncology, Immunology and Gastroenterology.
His work is dedicated to discovering how Internal medicine, Surgery are connected with Lenalidomide and other disciplines.
His work carried out in the field of Chronic lymphocytic leukemia brings together such families of science as Cancer and Cancer research.
William G. Wierda has included themes like [email protected], Imatinib, Myeloid leukemia and Minimal residual disease in his Oncology study.
As a part of the same scientific family, William G. Wierda mostly works in the field of Gastroenterology, focusing on Regimen and, on occasion, Vincristine and Hyper-CVAD.
His studies deal with areas such as Alemtuzumab and Ofatumumab as well as Fludarabine.
He most often published in these fields:
- Internal medicine (64.52%)
- Chronic lymphocytic leukemia (45.19%)
- Oncology (30.67%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.52%)
- Chronic lymphocytic leukemia (45.19%)
- Oncology (30.67%)
In recent papers he was focusing on the following fields of study:
William G. Wierda spends much of his time researching Internal medicine, Chronic lymphocytic leukemia, Oncology, Cancer research and Ibrutinib.
His research on Internal medicine often connects related topics like Gastroenterology.
His Chronic lymphocytic leukemia study combines topics in areas such as Neutropenia and Bruton's tyrosine kinase.
He interconnects Blinatumomab, Relapsed refractory, Disease and Transplantation in the investigation of issues within Oncology.
His research in Cancer research tackles topics such as Flow cytometry which are related to areas like STAT3.
The concepts of his Ibrutinib study are interwoven with issues in Obinutuzumab, Mantle cell lymphoma and B cell.
Between 2018 and 2021, his most popular works were:
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors (305 citations)
- Ibrutinib and venetoclax for first-line treatment of CLL (160 citations)
- Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. (72 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
William G. Wierda focuses on Chronic lymphocytic leukemia, Internal medicine, Cancer research, Oncology and Leukemia.
His Minimal residual disease research extends to Chronic lymphocytic leukemia, which is thematically connected.
His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
His research integrates issues of Waldenstrom macroglobulinemia, Apoptosis, Programmed cell death, [email protected] and Chimeric antigen receptor in his study of Cancer research.
The Oncology study combines topics in areas such as Cytarabine, Relapsed refractory, Disease, Blinatumomab and Acute lymphocytic leukemia.
His Leukemia research includes elements of CCL2, Cancer, Clinical trial, Myeloid leukemia and Lymphoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
